Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyridoxal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | HPGD | P15428 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 4/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.85 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.85 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.82 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | ACP1 | P24666 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.66 |
| ▸ | PDXK | O00764 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal SCHEMBL27627958 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL28454700 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL5051301 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL5498057 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL9559097 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL30616198 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL27131 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL18726347 | 0.98 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL8090165 | 0.97 | KDM4E (0.85) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL1065056 | 0.97 | KDM4E (0.85) | KDM4EALDH1A1LMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564978-B2 | Methods of treating a subject with an alkaline phosphatase deficiency | ALEXION PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20200179496-A1 | METHODS OF TREATING A SUBJECT WITH AN ALKALINE PHOSPHATASE DEFICIENCY | ALEXION PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10603361-B2 | Methods of treating a subject with an alkaline phosphatase deficiency | ALEXION PHARMACEUTICALS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| CN-106794148-B | The multi-mode delivery formulations of doxylamine and pyridoxol and/or its metabolite or salt | 达切斯内公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180333470-A1 | METHODS OF TREATING A SUBJECT WITH AN ALKALINE PHOSPHATASE DEFICIENCY | ALEXION PHARMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| CN-107550920-A | Angle conjunctiva protective agent or angle conjunctiva obstacle inhibitor | 东洋精糖株式会社 | 2018-01-09 | — | — | CN | disclosed |
| CN-104144690-B | Keratoconjunctiva protective agent or keratoconjunctival disorder inhibitor | 东洋精糖株式会社 | 2017-12-29 | — | — | CN | disclosed |
| EP-3250227-A2 | METHODS OF TREATING A SUBJECT WITH AN ALKALINE PHOSPHATASE DEFICIENCY | Alexion Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-106794148-A | The multi-mode delivery formulations of doxylamine and pyridoxol and/or its metabolite or salt | 达切斯内公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016123342-A2 | METHODS OF TREATING A SUBJECT WITH AN ALKALINE PHOSPHATASE DEFICIENCY | ALEXION PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| CN-104136004-A | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | DUCHESNAY INC | 2014-11-05 | — | — | CN | disclosed |
| JP-2004091473-A | THERAPEUTIC AGENT FOR IMPROVING CHROMATOSIS | TAKADA TADAYASU | 2004-03-25 | — | — | JP | disclosed |
| US-20040034042-A1 | Preservative composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034042-A1 | Preservative composition | XDH, XPA, SORBS1 | KDM4E 2017/4885ALDH1A1 714/4885LMNA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.